Heron sets November 3 results: Heron Therapeutics stock closed USD 0.30 on October 23, 2026

Published on 10/24/2026 at 19:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 37.67 million versus USD 42.19 million expected. Heron Therapeutics stock closed USD 0.30 on October 23, 2026 at 4 p.m. ET.

Reporting date and operating figures

Heron Therapeutics is scheduled to report third-quarter results on November 3, 2026.
Second-quarter revenue was USD 37.67 million versus USD 42.19 million expected.
Heron Therapeutics stock closed at USD 0.30 on October 23, 2026 at 4:00 p.m. ET.
Five analysts carried a Hold consensus and an average 12-month target of USD 2.00 on October 20, 2026.

HRTX, US4277461020, Illustration mit AI erstellt.

Heron sets November 3, 2026 for its next earnings report, while Heron Therapeutics stock closed at USD 0.30 on October 23, 2026 at 4:00 p.m. ET on Nasdaq. The scheduled report is the next dated test for revenue after second-quarter sales missed the published estimate.

According to MarketBeat, Heron is expected to report third-quarter revenue of USD 37.50 million and a loss of USD 0.03 per share on November 3, 2026. The same source lists a prior-year revenue figure of USD 38.21 million and a prior-year loss of USD 0.05 per share.

Revenue remains the central figure

Heron's second-quarter 2026 revenue was USD 37.67 million, while the estimate was USD 42.19 million. MarketBeat reported a second-quarter loss of USD 0.03 per share and a negative net margin of 22.52 percent. The quarterly figures are dated June 30, 2026.

Stock sits near its yearly low

MarketBeat listed a 52-week range of USD 0.26 to USD 1.57 on October 20, 2026. The USD 0.30 close therefore stood USD 0.04 above the low and USD 1.27 below the high. Finance data placed Heron's market capitalization at USD 57.5 million and volume at 1,308,526 shares on October 23, 2026.

The company is a biotechnology business focused on medicines for acute care and oncology-related supportive care. Its commercial portfolio includes ZYNRELEF and APONVIE, while CINVANTI addresses chemotherapy-induced nausea and vomiting.

Analyst view remains neutral

MarketBeat reported a Hold consensus from five analysts on October 20, 2026, with one sell, three hold and one buy rating. The average 12-month price target was USD 2.00. That target was USD 1.70 above the October 23 closing price, equal to 566.67 percent above it.

The next scheduled date is November 3, 2026, before the US market opens, with an earnings call listed for 8:30 a.m. ET. For investors, the key comparison will be whether third-quarter revenue of USD 37.50 million can approach the prior-year USD 38.21 million figure.

Nasdaq price and company profile

Heron Therapeutics, Inc. is listed on Nasdaq under ticker HRTX. Its latest Nasdaq closing price was USD 0.30 on October 23, 2026 at 4:00 p.m. ET. The company remains a small biotechnology issuer, with the November report providing the next quantified update on sales and earnings.